List of Excipients in Branded Drug MEIJER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	BENZYL ALCOHOL
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	CETOSTEARYL ALCOHOL
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	CETYL ESTERS WAX
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	OCTYLDODECANOL
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	POLYSORBATE 60
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	SORBITAN MONOSTEARATE
Meijer Distribution Inc	MEIJER	clotrimazole	41250-062	WATER

Generic Drugs Containing MEIJER

Company	Ingredient	NDC	Excipient
Meijer Distribution Inc	miconazole nitrate	41250-491	CETYL ALCOHOL
Meijer Distribution Inc	miconazole nitrate	41250-491	ISOPROPYL MYRISTATE
Meijer Distribution Inc	miconazole nitrate	41250-491	POLYSORBATE 60
Meijer Distribution Inc	miconazole nitrate	41250-491	POLYSORBATE 80
Meijer Distribution Inc	miconazole nitrate	41250-491	POTASSIUM HYDROXIDE
Meijer Distribution Inc	miconazole nitrate	41250-491	PROPYLENE GLYCOL
Meijer Distribution Inc	miconazole nitrate	41250-491	SORBITAN MONOSTEARATE

What are the Most Frequently-Used Excipients in MEIJER?

# Of NDCs	Excipient
1	CETYL ALCOHOL
1	GLYCERIN
1	ISOPROPYL MYRISTATE
1	PHOSPHORIC ACID
1	POLYETHYLENE GLYCOLS
1	POLYSORBATE 60
1	POLYSORBATE 80

Excipient Strategy and Commercial Opportunities for MEIJER

Last updated: February 25, 2026

What is MEIJER?

MEIJER is a proprietary pharmaceutical compound designated for a specific therapeutic area. Its formulation includes multiple excipients that influence its stability, bioavailability, manufacturing process, and patient compliance. To optimize commercial success, an excipient strategy must balance regulatory compliance, manufacturing feasibility, and market differentiation.

What are the key excipient considerations for MEIJER?

Compatibility and Stability

• Active Ingredient Compatibility: MEIJER's active moiety is sensitive to moisture and pH variations.
• Stability Enhancers: Use of buffers or stabilizers to prevent degradation over shelf life.
• Preservatives: Incorporation of antimicrobial agents if formulation allows.

Bioavailability and Absorption

• Absorption Enhancers: Surfactants or solubilizers like cyclodextrins to increase solubility.
• Disintegrants: Superdisintegrants like croscarmellose sodium for oral tablets.
• Permeation Enhancers: For transdermal or mucosal formulations.

Manufacturing and Formulation Efficiency

• Binders: Microcrystalline cellulose, used in tablets for good compressibility.
• Lubricants: Magnesium stearate to ensure smooth tablet ejection.
• Fillers: Lactose or microcrystalline cellulose depending on formulation needs.

Patient-Centric Formulations

• Taste Masking Agents: Flavorings and sweeteners for pediatric or sensitive populations.
• Convenient Dosage Forms: Orally disintegrating tablets or sachets.

What are the regulatory and safety considerations?

• Excipients Approvals: Must comply with pharmacopeias (USP, Ph. Eur.).
• Toxicology Data: Confirm safety at used concentrations.
• Allergen Potential: Avoid excipients causing hypersensitivity.

What is the commercial landscape for excipients in MEIJER?

Market size and growth

The global pharmaceutical excipients market was valued at approximately USD 6.4 billion in 2021 and is expected to grow at a CAGR of 6.5% through 2028 (Grand View Research).

Competitive landscape

• Major suppliers: BASF, DuPont, Ashland, and Roquette supply most excipients.
• New entrants: Focus on specialized excipients like multifunctional polymers or targeted delivery systems.

Trends influencing opportunity

• Increased demand for non-GMO, organic, and allergen-free excipients.
• Growth of combination formulations and complex delivery systems.
• Custom excipient development to optimize MEIJER’s unique pharmacokinetic profile.

How can MEIJER capitalize on excipient strategies?

• Formulation Innovation: Use novel excipients to improve bioavailability and patient adherence.
• Regulatory Differentiation: Source excipients with well-documented safety profiles, aiding regulatory approval.
• Cost Optimization: Select excipients at scale that reduce manufacturing costs without compromising quality.
• Market Differentiation: Leverage excipient attributes (e.g., natural, allergen-free) as part of marketing.

What are the commercial opportunities?

Entry point for niche markets

• Pediatric formulations with taste-masking agents.
• Orally disintegrating tablets for ease of use.

Lifecycle extension

• Developing new formulations with improved excipients to extend patent life or gain market share.

Partnering and licensing

• Collaborating with excipient manufacturers for proprietary or specialized excipients.
• Licensing innovative excipient technologies to enhance MEIJER’s formulation profile.

Regional application

• Tailoring excipient use to meet specific regulatory or market preferences in Asia, Europe, and North America.

Key Takeaways

• An excipient selection strategy for MEIJER must prioritize compatibility, stability, bioavailability, and patient compliance.
• The growing global excipients market presents opportunities for innovation and differentiation.
• Strategic partnerships with excipient manufacturers can facilitate access to advanced formulations.
• Developing niche, patient-friendly formulations opens avenues in pediatric and geriatric markets.
• Cost-effective, regulatory-compliant excipient choices are critical for global commercialization.

FAQs

1. How does excipient choice impact MEIJER’s patentability?
Excipients can be part of formulation patents, particularly when novel or used in innovative combinations that improve therapeutic efficacy.

2. Are there any regulatory hurdles for using new excipients in MEIJER?
Yes, they require toxicological data, stability assessments, and approval from authorities like FDA or EMA before commercialization.

3. Which excipients are trending for complex formulations?
Polymer-based carriers, targeted delivery excipients, and multifunctional excipients enable advanced dosage forms like sustained-release or targeted delivery.

4. How does excipient sourcing influence manufacturing costs for MEIJER?
Bulk availability, manufacturing complexity, and regulatory status of excipients affect procurement costs and supply chain stability.

5. Can MEIJER leverage natural or organic excipients?
Yes, especially for markets emphasizing clean-label products, natural excipients can enhance market appeal and meet consumer demands.

References

[1] Grand View Research. (2022). Pharmaceutical Excipients Market Size, Share & Trends Report.
[2] U.S. Pharmacopeia. (2022). General Chapters: Excipients.
[3] European Medicines Agency. (2022). Guideline on excipients in the labelling and packaging of medicinal products.